Loading…
The offering aims to raise capital through the sale of preferred stock and warrants.
Oragenics Inc. (NYSE: OGEN) announced a public offering to raise up to $20 million through the sale of preferred stock and warrants. The company intends to use the proceeds for general corporate purposes, which may include working capital, research and development, and potential acquisitions.
The offering consists of up to $20 million in preferred stock and accompanying warrants. Specific details regarding the pricing, number of shares, and exercise price of the warrants will be determined at the time of the offering. There are currently 4,068,600 shares in the free float and 4,168,200 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.